DRRX (DURECT Corporation) קצב צמיחת רווח למניה בשנה הנוכחית
Cash flows for DURECT Corporation (DRRX) are unstable due to a dependence on trial stages and licensing payments. The company is in the R&D stage without commercial sales, leading to a constant cash burn. The development of epigenetic liver treatments is accompanied by rising costs and negative leverage. Annual earnings per share growth reflects balance sheet volatility, where -163.90 indicates the level of this metric.
פילוחים אנליטיים ודוחות נתונים של חברת DURECT Corp. (DRRX)
The high sales potential of alcoholic hepatitis drugs makes DURECT Corporation (DRRX) dependent on profit dynamics. The analyzed year-over-year growth in net profit per share measures the percentage change in EPS, reflecting the pace of business capitalization. The positive trend on this chart confirms the effectiveness of the commercialization of developments. However, sharp fluctuations in the indicator signal risks associated with clinical trial outcomes. Steady growth of this metric enhances the fundamental stability of the asset.
